Transplantation· 2013Q1
Incidence and Impact of De Novo Donor-Specific Alloantibody in Primary Renal Allografts
- 372citations
- Q1SCImago
- 2013year
Short summary
In primary kidney transplant patients, 25% developed de novo donor-specific antibodies (dnDSA) within 10 years, with 20% incidence by 5 years and 24% graft loss within 3 years of dnDSA appearance.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Transplantation
TransplantationMedicine